Genmab A/S (GMAB)
Automate Your Wheel Strategy on GMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including GMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMAB
- Rev/Share 283.9994
- Book/Share 83.1065
- PB 17.0945
- Debt/Equity 0.027
- CurrentRatio 5.3399
- ROIC 0.9359
- MktCap 88265590001.3874
- FreeCF/Share 99.5834
- PFCF 13.9089
- PE 13.4841
- Debt/Assets 0.0217
- DivYield 0
- ROE 0.2561
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GMAB | Bernstein | Market Perform | Underperform | -- | -- | April 1, 2025 |
| Upgrade | GMAB | William Blair | Market Perform | Outperform | -- | -- | March 11, 2025 |
| Upgrade | GMAB | Leerink Partners | Market Perform | Outperform | -- | $27 | Feb. 13, 2025 |
| Initiation | GMAB | Redburn Atlantic | -- | Buy | -- | -- | Oct. 8, 2024 |
| Resumed | GMAB | Morgan Stanley | -- | Equal Weight | -- | $31 | Sept. 4, 2024 |
| Downgrade | GMAB | JP Morgan | Overweight | Neutral | -- | -- | Aug. 20, 2024 |
News
Why Genmab Stock Smashed It on Monday
Published: June 02, 2025 by: The Motley Fool
Sentiment: Neutral
On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (GMAB 3.94%), on the back of encouraging news from the laboratory.
Read More
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 months Continued evaluation of single-agent Rina-S 100 mg/m 2 in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be further evaluated in a planned Phase 3 trial Genmab A/S (Nasdaq: GMAB ) announced today new data from cohort B2 of the Phase …
Read More
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months, treatment with Rina-S 100 mg/m2 every 3 weeks (Q3W) resulted in a 50.0 percent confirmed objective response rate (ORR), including two complete.
Read More
Transactions in Connection with Share Buy-back Program
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; May 27, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the 4 6 th Goldman Sachs Annual Global Health c are Conference in Miami, Florida at 8:00 A M E D T ( 2:00 PM CE S T ) on June 9 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Read More
Transactions in Connection with Share Buy-back Program
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S ® ) in patients with recurrent/advanced endometrial cancer Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Genmab A/S (Nasdaq: GMAB ) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations …
Read More
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRa)-.
Read More
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; May 21, 2025 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference in New York City, New York at 9:20 EDT ( 3 : 2 0 PM CE S T) on June 5 , 2025. A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Transactions in Connection with Share Buy-back Program
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab has promising proprietary antibody platforms and partnerships that have helped it transition from licensor to commercial-stage biotech. Their robust royalty stream from Darzalex and Kesimpta funds R&D, while net product sales of epcoritamab and Tivdak are quickly growing as well. Their late-stage pipeline includes epcoritamab label expansions, Rina-S in ovarian cancer, and Acsunilimab in NSCLC. Each of these candidates targets large TAMs.
Read More
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; May 14, 2025 Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab A/S (Nasdaq: GMAB ) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination across disease settings in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) at the 30th European Hematology Association (EHA) Congress, being held in Milan, Italy, and virtually, June 12-15, 2025. Two oral presentations will feature data from the Phase …
Read More
Transactions in Connection with Share Buy-back Program
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab Announces Financial Results for the First Quarter of 2024
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025
Read More
GMAB or RGEN: Which Is the Better Value Stock Right Now?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Read More
Should Value Investors Buy Genmab (GMAB) Stock?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Published: March 31, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic.
Read More
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Published: March 27, 2025 by: Benzinga
Sentiment: Positive
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S' GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.
Read More
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Published: March 27, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan. In recent years, cervical cancer incidence and mortality rates have increased in Japan, particularly among women un.
Read More
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Published: March 14, 2025 by: Seeking Alpha
Sentiment: Negative
Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Concerns about GEN3014's safety may have impacted investors' perceptions of Genmab's HexaBody platform.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 13,926 restricted stock units to members of the Board of Directors and employees of the Company and the Company's subsidiaries and 4,214 warrants to the employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right …
Read More
Passing of Genmab A/S' Annual General Meeting
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management and the year's profit was carried forward The 2024 Compensation Report was approved Six members of the Board of Directors were re-elected Deloitte was re-elected as the auditor of the Company The proposal from the Board of Directors to adopt amendments to the Remuneration Policy, the proposal on the Board of Directors' remuneration for 2025, the proposal to reduce the Company's share capital with nominally DKK 2,076,853 by …
Read More
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Published: March 10, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab's rigorous portfolio prioritization, Genmab will not pursue f.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 517,191 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects.
Read More
Notice to Convene the Annual General Meeting of Genmab A/S
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy is attached.
Read More
About Genmab A/S (GMAB)
- IPO Date 2009-06-01
- Website https://www.genmab.com
- Industry Biotechnology
- CEO Dr. Jan G.J. van de Winkel Ph.D.
- Employees 2638